Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ocugen Inc

OCGN ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$1.35

▲ +0.00%

Market Cap $457.80M · Vol 672.14K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$457.80M

Small Cap

Div Yield

N/A

EPS Growth

-2.90%

YoY

RSI (14)

58.49

Momentum

Beta

2.21

vs Market

52W High

$2.72

50.37% below

52W Low

$0.98

37.73% above

Volume

672.14K

Avg 1.27M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

98.31%

Public shares

Shariah Compliance8 STANDARDS

✗ Ocugen Inc (OCGN) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OCGN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.47%

-5.59%

-7.53%

-4.26%

YTD

+0.00%

+31.07%

+183.43%

-81.81%

Financials & Valuation

TTM · Annual

Total Revenue	$4.41M
Net Income	$-67,846,000.00
Revenue Growth (YoY)	+8.38%
Gross Margin	100.00%
Operating Margin	-1,425.70%
Net Profit Margin	-1,537.41%
ROE	N/A
ROA · ROIC	-107.73% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	91.83
P/B	N/A
P/FCF	N/A
EPS Growth	-2.90%
Outstanding Shares	339.11M

Technical Indicators

50-Day SMA	$1.34
200-Day SMA	$1.51
RSI (14)	58.49
Beta	2.21
52-Week High	$2.72
52-Week Low	$0.98

Volume Today	672.14K
Avg Daily Volume (30D)	1.27M
Relative Volume	0.53x
Volatility (10D)	46.04
Volatility (30D)	45.17
Free Float	98.31%

Analyst Consensus

BUY

Current Price $1.35

Mean Target $12.17

52W Low$0.98 52W High$2.72

Current

Target

$0.98 $2.72

Current Analyst target

+801.23% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001TG1LS2

ISINUS67577C1053

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.